摘要
Immunotherapyhasbecomeakeystrategyforcancertreatment,andtwoimmunecheckpoints,namely,programmedcelldeath1(PD-1)anditsligand(PD-L1),haverecentlyemergedasimportanttargets.TheinteractionblockadeofPD-1andPD-L1demonstratedpromisingactivityandantitumorefficacyinearlyphaseclinicaltrialsforadvancedsolidtumorssuchasnon-smallcelllungcancer(NSCLC).ManycelltypesinmultipletissuesexpressPD-L1aswellasseveraltumortypes,therebysuggestingthattheligandmayplayimportantrolesininhibitingimmuneresponsesthroughoutthebody.Therefore,PD-L1isacriticalimmunomodulatingcomponentwithinthelungmicroenvironment,butthecorrelationbetweenPD-L1expressionandprognosisiscontroversial.MoreevidenceisrequiredtosupporttheuseofPD-L1asapotentialpredictivebiomarker.ClinicaltrialshavemeasuredPD-L1intumortissuesbyimmunohistochemistry(IHC)withdifferentantibodies,buttheassessmentofPD-L1isnotyetstandardized.Somecommercialantibodieslackspecificityandtheirreproducibilityhasnotbeenfullyevaluated.FurtherstudiesarerequiredtoclarifytheoptimalIHCassayaswellastopredictandmonitortheimmuneresponsesofthePD-1/PD-L1pathway.
出版日期
2015年02月12日(中国Betway体育网页登陆平台首次上网日期,不代表论文的发表时间)